๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
NCT05345522Idiopathic Multicentric Castleman's Disease
Beijing VDJBio Co., LTD.
Phase 2
25
Beijing, Chengdu
2022-04-18
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Recruiting
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Active, closed
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051Neoplasms
GlaxoSmithKline
Phase 1
152
Chengdu, Jinan, Shanghai, Wuhan
2022-03-22
By invitation
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT06707922Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05262400Breast Cancer, Solid Tumors
Pfizer
Phase 1/2
235
Changchun, Shanghai, Chengdu, Tianjin, Hangzhou
2022-03-14
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Active, closed
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NCT05280470Extensive-stage Small-cell Lung Cancer
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo
Phase 3
740
Nanning, Zhengzhou, Changchun, Chengdu, Beijing, Cangzhou, Changsha, Chongqing
2022-03-04
Active, closed
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05092412Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
You Lu
Phase 2
30
Chongqing, Zhengzhou, Chengdu
2022-03-02
Recruiting
THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein
NCT05194423Tricuspid Valve Regurgitation
Changhai Hospital
Not applicable
150
Beijing, Guangzhou, Wuhan, Xi'an, Shanghai, Chengdu, Hangzhou
2022-03-01
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
Janssen Research & Development, LLC
Phase 2
151
Beijing, Chengdu, Hangzhou, Shanghai
2022-03-01
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Active, closed
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
NCT05393427Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
4
Beijing, Chongqing, Chengdu
2022-02-15
Recruiting
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206Pruritus
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
NCT05262491Gastrointestinal Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
Janssen Research & Development, LLC
Phase 3
350
Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou
2022-01-19
Recruiting
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
NCT07014943Primary Central Nervous System Lymphoma (PCNSL)
Sichuan University
Phase 2
34
Chengdu
2022-01-01
Active, closed
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
NCT05054439Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Active, closed
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
NCT05615142NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy, PD-1 Inhibitor
Sichuan University
Phase 1
9
Chengdu
2021-12-15
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
GlaxoSmithKline
Phase 2
360
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Liuzhou
2021-12-14
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Recruiting
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
NCT04902248Upper Gastrointestinal Bleeding
Chinese University of Hong Kong
Not applicable
236
Beijing, Nanchang, Chengdu
2021-11-27
Active, closed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
NCT05160545Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Bengbu, Dongguan, Guangzhou, Changsha, Chengdu
2021-11-26
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Active, closed
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals
Phase 3
153
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu
2021-11-15
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Recruiting
A Study of HG381 Administered to Patients With Advanced Solid Tumors
NCT04998422Advanced Solid Tumor
HitGen Inc.
Phase 1
57
Chengdu
2021-10-18
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Active, closed
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Active, closed
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
NCT05056402Cervical Cancer, Condylomata Acuminata
Xiamen University
Phase 3
1,382
Chengdu
2021-09-19
Active, closed
A Study of KL590586 in Patients With Advanced Solid Tumors
NCT05265091Advanced Solid Tumor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
414
Chengdu
2021-09-15
Active, closed
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
NCT04995523Non-Small-Cell Lung Carcinoma
AstraZeneca
Phase 1/2
212
Chengdu, Chongqing
2021-09-14
Active, closed
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811Non Small Cell Lung Cancer
Nuvation Bio Inc.
Phase 2
217
Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan
2021-09-01
Recruiting
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05445154Newly Diagnosed Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
58
Chengdu
2021-08-31
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
Hoffmann-La Roche
Phase 3
4,170
Zhengzhou, Changsha, Nanchang, Changchun, Shanghai, Chengdu, Hangzhou, Beijing
2021-08-27
Active, closed
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
NCT04922853Rectal Cancer, Neoadjuvant Chemotherapy
West China Hospital
Phase 3
554
Wuxi, Chengdu, Kunming
2021-08-26
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-08-14
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
Merck Sharp & Dohme LLC
Phase 2
355
Beijing, Guangzhou, Shanghai, Chengdu
2021-08-12
By invitation
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
NCT04762459Non-small Cell Lung Carcinoma
Chinese Academy of Medical Sciences
Phase 3
606
Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-08-01
Recruiting
The GUARDIAN Trial
NCT04884802Blood Pressure
The University of Texas Health Science Center, Houston
Not applicable
6,254
Beijing, Chengdu, Hong Kong, Shanghai, Xuzhou
2021-07-25
Active, closed
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
NCT05712902Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Active, closed
Evolut PRO China Clinical Study
NCT04982588Severe, Symptomatic Aortic Stenosis
Medtronic Cardiovascular
Not applicable
52
Beijing, Chengdu, Hangzhou
2021-07-17
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Active, closed
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
NCT05189730Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2
80
Chengdu
2021-07-01
Active, closed
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248Primary Membranous Nephropathy
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
Novartis Pharmaceuticals
Phase 3
1,140
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Active, closed
Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)
NCT04765592Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Recruiting
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
NCT06482086Locally Advanced Thyroid Gland Carcinoma
West China Hospital
Phase 2
75
Chengdu
2021-06-01
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
AstraZeneca
Phase 3
366
Baoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang
2021-05-31
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
893
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2021-05-10
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Recruiting
Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease
NCT06819410Invasive Fungal Disease
Sichuan Provincial People's Hospital
Observational
1,000
Chengdu
2021-05-01
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2021-04-26
Active, closed
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
NCT04649489Venous Thrombosis
Jia Fan
Phase 3
501
Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei
2021-04-19
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
NCT04794972Recurrent Glioma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Guangzhou, Shenzhen, Xian, Chengdu
2021-04-14
Recruiting
Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer
NCT04527861Colorectal Cancer, Colon Cancer, Rectal Cancer
Ruijin Hospital
Not applicable
710
Lanzhou, Shenyang, Jinan, Chengdu, Hangzhou, Shanghai
2021-04-08
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2021-03-18
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010Relapsing Multiple Sclerosis
Hoffmann-La Roche
Phase 3
746
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Kunming
2021-03-17
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
NCT04654468Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
51
Chengdu, Guangzhou, Tianjin, Wuhan
2021-03-17
Active, closed
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Recruiting
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
NCT04684459Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant, HER2 Positive Malignancies
Sichuan University
Phase EARLY_PHASE1
18
Chengdu
2021-03-12
Recruiting
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 1
304
Changchun, Chengdu, Fuzhou, Shandong, Shanghai, Zhengzhou
2021-03-09
Recruiting
PM8002 in the Treatment of Patients With Advanced Solid Tumors
NCT05918445Malignant Neoplasm
Biotheus Inc.
Phase 1/2
380
Baoji, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing
2021-03-09
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Recruiting
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
NCT04444349Cardiovascular Disease
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu
2021-02-01
Active, closed
A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon
NCT04826705Drug-coated Balloon, Femoropopliteal Artery Occlusion, Angioplasty
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
2,000
Wuhan, Beijing, Chengdu, Hangzhou, Qingdao, Shanghai, Suzhou
2021-02-01
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-01-28
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
Hoffmann-La Roche
Phase 2
920
Beijing, Chengdu, Shanghai, Tianjin, Xi'an
2021-01-18
Recruiting
The Application of Artificial Intelligence in Wrist and Hand Joint Ultrasound
NCT06883669Education, Joint Diseases
West China Hospital
Observational
500
Chengdu
2021-01-01
Recruiting
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy
NCT07309991Esophageal Carcinoma, Esophageal Adenocarcinoma, Esophagectomy, PaO2
Sun Yat-sen University
Observational
2,500
Guangzhou, Shantou, Shijiazhuang, Shanghai, Chengdu, Nanchong
2021-01-01
Recruiting
Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)
NCT04699279Acute Aortic Syndrome, Aortopathy
Nanjing Medical University
Not applicable
300
Guangzhou, Nanjing, Qingdao, Chengdu, Beijing
2021-01-01
Active, closed
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
NCT04765605Type B Aortic Dissection
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
120
Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei
2020-12-25
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Dongguan, Fuzhou, Baotou, Nanjing, Nantong, Shanghai, Chengdu, รœrรผmqi
2020-12-11
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
518
Beijing, Changchun, Changsha, Changsha Shi, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-12-07
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Active, closed
Postoperative Thrombosis Prevention in Patients With CD
NCT04486859Cushing Disease, DVT, Pulmonary Embolism
Huashan Hospital
Not applicable
206
Fuzhou, Guangzhou, Wuhan, Shanghai, Chengdu, รœrรผmqi, Beijing
2020-12-01
Recruiting
Durg Coated Balloon Angioplasty in Infrapopliteal Lesions
NCT05620095Arteriosclerosis, Peripheral Artery Disease, Chronic Limb Threatening Ischemia
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
1,000
Beijing, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu, Hangzhou
2020-12-01
Active, closed
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986Metastatic Breast Cancer
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
NCT04606472Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu
2020-11-10
Recruiting
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT04586478Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
Phase 2
60
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Jinan, Shanghai, Chengdu
2020-10-26
Active, closed
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
NCT04454437Metastatic Triple-negative Breast Cancer
Gilead Sciences
Phase 2
80
Beijing, Shenyang, Hangzhou, Changchun, Changsha, Chengdu, Chongqing, Guangzhou
2020-10-23
Active, closed
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
NCT04550260Esophageal Squamous Cell Carcinoma
AstraZeneca
Phase 3
640
Anyang, Beijing, Bengbu, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2020-10-19
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
308
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-10-13
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Recruiting
Assessment System for Sarcopenia Based on Ultrasonographic Data
NCT06199856Sarcopenia, Ultrasound
West China Hospital
Observational
1,500
Chengdu
2020-10-01
Recruiting
Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients
NCT06599346Mucositis, Hematopoietic Stem Cell Transplantation, Chemotherapy-Induced Mucositis, Radiation-Induced Mucositis
The General Hospital of Western Theater Command
Not applicable
120
Chengdu
2020-10-01
Rows per page Showing 1101–1200 of 1291
Previous 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=12

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.